China To Tighten Control Over Stimulants
This article was originally published in PharmAsia News
In China's continuous crack down on illegal production and trading of stimulants, China's State FDA, State Administration for Industry & Commerce, Ministry of Industry & Information Technology and Ministry of Public Security have jointly announced that effective June 19, all chemical companies should not produce or deal with prohibited substances in the catalog of stimulants without permission. Online advertising and sales of such products, including protein assimilation preparations and peptide hormones, are also strictly prohibited. China will further intensify inspection work: eight ministries including the Ministry of Health and SFDA will inspect the stimulant management of the six Olympics host cities from late June to early July; investigation and confirmation of contraband will lead to heavy prosecution; and telephone number and email address will be publicized for informants. (Click here for more - Chinese Language)
You may also be interested in...
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.
The Global Self-Care Federation is looking to consolidate the shift towards self-care seen during the pandemic by promoting trust, innovation and growth in policy. An upcoming webinar hosted by the GSCF will also explore the theme of "Advancing Trust in the Self-Care Industry."
After seeing a spike in demand due to the coronavirus pandemic in Q1, with a corresponding dip in Q2, the generics industry has largely seen single-digit drops in net revenues in the third quarter of 2020. Meanwhile, the Indian pharma market has seen recovery after facing a challenging coronavirus-induced slump in the first two quarters of 2020.